Company

Skyhawk Therapeutics

Waltham-based Skyhawk Therapeutics develops small molecules that modify RNA expression for neurology, oncology and fibrotic diseases.

About

Founded in 2016 by Bill Haney and based in Waltham, Massachusetts, Skyhawk Therapeutics develops small molecules that modify RNA expression, mainly for neurology, oncology and fibrotic diseases. Its candidates include SKY-0515 for Huntington's Disease, and the company collaborates with BMS, Biogen and Sanofi. The company raised USD 133.00 mn on September 14, 2021, led by Fidelity Management and Research Company, with Rock Springs Capital and GreatPoint Ventures.

3Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in